发布求助
文献互助 智能选刊 最新文献

The Brown University Psychopharmacology Update最新文献

筛选
英文 中文
Suvorexant, lemborexant effective for preventing delirium in hospital patients 苏伐生坦、连伯生坦可有效预防医院病人谵妄
The Brown University Psychopharmacology Update Pub Date : 2024-10-01 DOI: 10.1002/pu.31233
{"title":"Suvorexant, lemborexant effective for preventing delirium in hospital patients","authors":"","doi":"10.1002/pu.31233","DOIUrl":"https://doi.org/10.1002/pu.31233","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 11","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142404154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis identifies factors associated with response to ketamine for TRD 分析确定与氯胺酮治疗TRD反应相关的因素
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31210
{"title":"Analysis identifies factors associated with response to ketamine for TRD","authors":"","doi":"10.1002/pu.31210","DOIUrl":"https://doi.org/10.1002/pu.31210","url":null,"abstract":"<p>Outpatient treatment initiators and individuals with moderately severe or severe pretreatment depression were most likely to benefit from ketamine treatment over electroconvulsive therapy (ECT) for treatment-resistant depression (TRD), a newly published analysis has found. Individuals with the most severe pretreatment depression saw greater benefit from ECT early in treatment. Study results were published online June 25, 2024, in <i>JAMA Network Open</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic-associated breast cancer 与抗精神病药相关的乳腺癌
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31212
Y. W. Francis Lam Pharm.D., FCCP
{"title":"Antipsychotic-associated breast cancer","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31212","DOIUrl":"https://doi.org/10.1002/pu.31212","url":null,"abstract":"<p>Research data suggest an association between antipsychotic-induced hyperprolactinemia and higher risk of breast cancer (Rahman et al., 2022; also, see “Breast cancer risk with antipsychotic use linked to prolactin levels;” https://doi.org/10.1002/pu.30853). This is likely secondary to the anti-dopaminergic properties of antipsychotics, especially those of first-generation agents.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Your Medication Information 您的用药信息
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31222
{"title":"Your Medication Information","authors":"","doi":"10.1002/pu.31222","DOIUrl":"https://doi.org/10.1002/pu.31222","url":null,"abstract":"<p>Citalopram (generic) — Celexa (brand)</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidepressants for bipolar depression do not increase risk of mania 治疗双相抑郁症的抗抑郁药不会增加躁狂症风险
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31220
{"title":"Antidepressants for bipolar depression do not increase risk of mania","authors":"","doi":"10.1002/pu.31220","DOIUrl":"https://doi.org/10.1002/pu.31220","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benzodiazepine use not associated with increased risk of dementia 使用苯二氮卓与痴呆症风险增加无关
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31217
{"title":"Benzodiazepine use not associated with increased risk of dementia","authors":"","doi":"10.1002/pu.31217","DOIUrl":"https://doi.org/10.1002/pu.31217","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral formulation of ketamine effective for treatment-resistant depression 氯胺酮口服制剂对耐药性抑郁症有效
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31215
{"title":"Oral formulation of ketamine effective for treatment-resistant depression","authors":"","doi":"10.1002/pu.31215","DOIUrl":"https://doi.org/10.1002/pu.31215","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tirzepatide reduces sleep events in patients with sleep apnea and obesity 替扎帕肽可减少睡眠呼吸暂停和肥胖症患者的睡眠事件
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31214
{"title":"Tirzepatide reduces sleep events in patients with sleep apnea and obesity","authors":"","doi":"10.1002/pu.31214","DOIUrl":"https://doi.org/10.1002/pu.31214","url":null,"abstract":"<p>Two Phase 3 trials have found that tirzepatide, a medication used to treat type 2 diabetes, reduced apnea events and body weight in patients with obstructive sleep apnea and obesity. Tirzepatide had comparable safety results to placebo in the two trials.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidepressant discontinuation led to adverse symptoms one-third of the time 三分之一的患者在停用抗抑郁药后出现不良症状
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31211
{"title":"Antidepressant discontinuation led to adverse symptoms one-third of the time","authors":"","doi":"10.1002/pu.31211","DOIUrl":"https://doi.org/10.1002/pu.31211","url":null,"abstract":"<p>A systematic review and meta-analysis encompassing 79 studies has found that around one-third of patients who discontinue antidepressant medication will experience adverse symptoms, but only around 1 in 30 will experience severe discontinuation symptoms. An analysis of individual antidepressants found that imipramine, desvenlafaxine, and venlafaxine were associated with the highest incidence of discontinuation symptoms. Results were published online June 5, 2024, in <i>Lancet Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topiramate compares favorably to naltrexone for alcohol use disorder 托吡酯与纳曲酮相比，在治疗酒精使用障碍方面效果更佳
The Brown University Psychopharmacology Update Pub Date : 2024-09-04 DOI: 10.1002/pu.31213
{"title":"Topiramate compares favorably to naltrexone for alcohol use disorder","authors":"","doi":"10.1002/pu.31213","DOIUrl":"https://doi.org/10.1002/pu.31213","url":null,"abstract":"<p>A 12-week randomized trial involving 147 participants has found that topiramate was as effective as naltrexone in reducing drinking behaviors in patients with alcohol use disorder (AUD). A secondary analysis found no association between two gene poly­morphisms and patient response to the medication treatments.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142137651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信